drugset / Trial / NCT02962492
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
RandomizedParallel-groupTriple-blindBasic science
Summary
The study investigations include evaluation of the acute effects of a single dose of dapagliflozin (10mg), exenatide (5µg), a combination of exenatide and dapagliflozin or placebo under insulinopenic condition and the long term effect under basal conditions before and after 12 weeks treatment with dapagliflozin, Exenatide extended release, a combination of Exenatide extended release and dapagliflozin or placebo on ketogenesis, glucagon and lipolysis.
Timeline
- Start
- 2016-11-01
- Primary completion
- 2021-02-01
- Completion
- 2021-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Exenatide | Peptide | 5 ug | Subcutaneous |
Indications
No indication recorded.